Evidence map›Paper›PMID 38405698›Full record

ArticlebioRxiv : the preprint server for biology2024

Diverse

James F Clark, Philippe Soriano

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

James F ClarkDepartment of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-8659-6348
Philippe SorianoDepartment of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-0427-926X
Icahn School of Medicine at Mount Sinai · US

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
FGF Signaling Pathways and Craniofacial DevelopmentR01DE022778 · NIDCR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SORIANO, PHILIPPE M · 2012 to 2022
$6.6M
Novel Effectors of FGF Signaling in Craniofacial DevelopmentF32DE029387 · NIDCR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CLARK, JAMES · 2020 to 2022
$208k
NCI NIH HHS P30 CA196521NIDCR NIH HHS F32 DE029387NIDCR NIH HHS R01 DE022778
6 · The paper itself

Abstract

The Fibroblast growth factor (FGF) pathway is a conserved signaling pathway required for embryonic development. Activated FGF receptor 1 (FGFR1) drives multiple intracellular signaling cascade pathways, including ERK/MAPK and PI3K/AKT, collectively termed canonical signaling. However, unlike

Indexed as

cell adhesioncell signalingendocytic traffickingFGFkidney developmentmesoderm development

Identifiers

PMID38405698
PMCPMC10888970
OpenAlexW4391884987

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.